Nebula AeAH AI turns the peer-reviewed literature into an interactive map of any technology, compound, or indication — so investment teams can see, in minutes, how much published science supports a start-up's claims.
A quick, visual read on the published evidence behind a deal — before the deep dive begins.
Type any technology, compound, or indication and Nebula AeAH AI pulls live publication data, then lays it out as an explorable 3D map.
Papers are automatically classified into eight disease areas and connected by topical relatedness, exposing where the evidence is — and isn't.
Every map is fully grounded in real papers — every entry resolves to a DOI you can open. Export the corpus as ZIP (full corpus plus links) or CSV (the paper list) for your own diligence notes and models.
Consult Sciences Ltd provides scientific and technical consulting to biotech and life-science companies, investors, and research organizations. Our work spans literature and patent intelligence, scientific due diligence, and technical strategy.
Nebula AeAH AI is our first public product — a beta built to demonstrate the publication-intelligence work we do behind the scenes, packaged into a tool investment teams can use directly.
Nebula AeAH AI is currently in beta: fully functional, but still evolving. During the beta we are:
Request access below — beta participants get early access, priority feature input, and a free window into the paid release.
Tell us a little about you and how you'd use Nebula AeAH AI. We typically respond within two business days.
Fields marked * are required. We'll reply to your work email within two business days.
Already have an account? Sign in.
Nebula AeAH AI visualizes published research as an evidence-mapping aid. It does not constitute investment, scientific, or legal advice.